Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

July 1, 2026

Conditions
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Interventions
DRUG

Tocilizumab

Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.

DRUG

Prednisone

Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage

Trial Locations (1)

300052

RECRUITING

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER